Comparing major COPD triple therapy trials using a structured multi-criteria decision analysis: A deep dive into patient populations and outcomes - 01/09/25
, Mauro Maniscalco b, c, Vincenzo Patella d, e, Luigino Calzetta f, Maria Gabriella Matera g, Paola Rogliani aAbstract |
Background |
Triple inhaled therapy (ICS/LABA/LAMA) is widely recommended for managing COPD in patients with persistent symptoms or frequent exacerbations. However, variability in trial designs, populations, and pharmacologic formulations complicates direct comparison between regimens.
Objective |
To evaluate the comparative performance of three triple therapies, FF/VI/UMEC, BUD/FOR/GLY, and BDP/FOR/GLY, using a multidimensional comparative decision analysis (MCDA) across key clinical domains.
Methods |
Data from pivotal trials (IMPACT, FULFIL, TRINITY, TRIBUTE, TRILOGY, ETHOS, and KRONOS) were synthesized using an MCDA framework encompassing lung function, symptom control, and exacerbations. Mortality, safety, and device usability were also assessed. Analyses considered variations in enrolled populations, prior ICS use, and inhaler characteristics.
Results |
FF/VI/UMEC showed consistent efficacy across multiple domains and populations, particularly in patients at high risk of exacerbations. BUD/FOR/GLY was associated with reductions in exacerbations and mortality, particularly in patients previously treated with LABA/LAMA. BDP/FOR/GLY may be suitable for ICS-maintained patients. Trials like FULFIL and KRONOS showed symptom and lung function gains even in non-exacerbators, although ICS use in this group always warrants caution due to pneumonia risk.
Limitations |
Findings are based on indirect comparisons across heterogeneous trials. Relative changes from dual therapy comparators were evaluated, and pharmacological and device-related differences between each triple therapy and the comparators may have influenced outcomes.
Conclusions |
Among the therapies evaluated, FF/VI/UMEC achieved the highest composite MCDA score. However, optimal COPD management requires personalized treatment to be prescribed based on factors such as exacerbation history, previous ICS use, inhaler preference and adherence. This may involve evaluating the use of an alternative triple therapy and emphasizes the importance of aligning the choice of triple therapy with the individual's clinical profile and treatment goals.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Triple therapy is key for COPD patients with persistent symptoms or frequent exacerbations. |
• | Three triple therapies, FF/VI/UMEC, BUD/FOR/GLY, and BDP/FOR/GLY, have been approved. |
• | The substantial differences in pivotal RCTs make it difficult to compare these therapies. |
• | MCDA offers comparative insights into triple therapies, highlighting their distinct profiles. |
• | Despite limitations, findings provide a basis for selecting the best triple therapy. |
Plan
Vol 247
Article 108292- octobre 2025 Retour au numéro
Article précédent
- Association of aspirin use with mortality in critically ill patients with chronic obstructive pulmonary disease: A retrospective propensity score-matched cohort study
- Shaolin Cai, Qingcui Huang, Minna Huang, Jinghao Wang, Shasha Li
- Impact of cancer treatment on physical functioning, symptoms and health-related quality of life in patients with non-small cell lung cancer: A longitudinal observational study
- Kirsten Quadflieg, Eva Arents, Sarah Haesevoets, Francesca Van Hulle, Fien Hermans, Maarten Criel, Marc Daenen, Eric Derom, Martijn A. Spruit, Veerle Surmont, Dieter Stevens, David Ruttens, Heleen Demeyer, Chris Burtin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?